A Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ALKS 7119 in Healthy Male Adults

Published: 10-12-2015
Last updated: 19-04-2024

To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ALKS 7119 following oral administration of single ascending doses of ALKS 7119 in healthy male adults

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Neurological disorders NEC
Study type	Interventional

Summary

ID

NL-OMON43993

Source
ToetsingOnline

Brief title
Single ascending dosis study of ALKS 7119

Condition

- Neurological disorders NEC
- Dementia and amnestic conditions

Synonym
Alzheimer's disease, Dementia

Research involving
Human

Sponsors and support

Primary sponsor: Alkermes, Inc.
Source(s) of monetary or material Support: Alkermes;Inc.

Intervention

Keyword: ALKS7119, Pharmacodynamics, Pharmacokinetics, Safety

Outcome measures

Primary outcome

At a minimum, the following PK parameters will be determined for ALKS 7119.

* Cmax

* Time to Cmax (Tmax)

* Terminal elimination half-life (t*)

* Area under the concentration-time curve from time zero to the last

quantifiable time interval (AUClast)

* Area under the concentration-time curve from time zero to infinity (AUC*)

Additional PK parameters may be determined as appropriate.

The pharmacodynamics of ALKS 7119 will be evaluated via a battery of tasks, including saccadic eye movements, smooth pursuit eye movements, adaptive tracking performance test, pupillometry, Visual Analog Scales (Bond and Lader, and Bowdle scales), the Visual Verbal Learning Test, and pharmaco-electroencephalography (EEG). In addition, blood cortisol measurements will be collected.

Evaluation of safety will be based on vital signs, blood clinical biochemistry

and hematology, urinalysis, physical examinations, safety 12-lead

electrocardiograms (ECGs), real-time ECG monitoring, and adverse events (AEs).

Secondary outcome

NA

Study description

Background summary

Emerging studies point to a potential role for NMDA antagonists in treating behavioral symptoms associated with Alzheimer*s disease, including agitation [Cummings, 2014;Wilcock, 2008]. There are currently no approved drugs in the US for treating these symptoms, which diminish quality of life for patients and caretakers and correlate with a poorer disease prognosis. Developing drugs for this indication therefore represents a significant clinical need. As a low-affinity antagonist at the NMDA receptor, Alkermes postulates that ALKS 7119 may be applicable for this purpose.

Study objective

To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ALKS 7119 following oral administration of single ascending doses of ALKS 7119 in healthy male adults

Study design

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of single ascending doses of ALKS 7119 in healthy male adults. Up to 10 cohorts are planned with 10 subjects per cohort and a total of 100 randomized subjects.
Potential subjects will be screened up to 21 days prior to administration of study drug. Dosing of cohorts will be separated by at least 7 days to allow adequate time for a review of all safety, PD, and PK data from the most recently dosed cohort.
The study duration for a given subject is expected to be up to 4.5 weeks, which includes up to 3 weeks for screening, an inpatient stay from Day -1 to Day 2, and a follow-up visit between Day 8 and 11.

Intervention

The subjects will receive a single dose of ALK 7119 or placebo.

Study burden and risks

There is no health benefit for participants. Risk is considered minimal. Burden consists of time investment and life style restrictions.

Contacts

Public
Alkermes, Inc.

Winter Street 852
Waltham MA 02451
US
Scientific
Alkermes, Inc.

Winter Street 852
Waltham MA 02451
US

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Is willing and able to give informed consent
2. Is capable of understanding and complying with the protocol
3. Is male, and *18 and *45 years of age at screening

4. Has a body-mass index *18.0 and *32.0 kg/m2 at screening
5. Agrees to use an acceptable method of contraception for the duration of the study as outlined in Section 9.4.1 of the protocol and for 90 days after any study drug administration

Exclusion criteria

1. Has a clinically significant medical condition or observed abnormalities in the opinion of the Investigator (including physical examination results, vital sign results, ECG results, laboratory blood sample test results [particularly kidney function, liver function, and hematology test results], and urinalysis)
2. Has a corrected QT interval (Fridericia correction; QTcF) t;450 milliseconds, PR interval t;220 milliseconds, or any other ECG finding that, in the opinion of the investigator, might compromise subject safety
3. Has a thyroid stimulating hormone (TSH) level greater than 10% above or below the normal range at screening
4. Has a history of intolerance or hypersensitivity to dextromethorphan or any dextromethorphan-containing product
5. Has had a clinically significant illness in the 30 days prior to first study drug administration (Day 1)
6. Has a positive drug screen for alcohol, amphetamines, methamphetamine, barbiturates, benzodiazepines, cocaine, tetrahydrocannabinol (THC), methadone, or opiates at screening or upon inpatient admission
7. Has a positive serology test for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus antibody (HIVAb) at screening
8. Has a lifetime history of diabetes or Hemoglobin A1c (glycosylated hemoglobin) >6% at screening
9. Has used any prescription or over-the-counter medication, including herbal remedies and nutritional supplements (except vitamins), within 7 days prior to screening or inpatient admission
10. Has ingested any alcohol, caffeine, or xanthine within 24 hours prior to inpatient admission, or excessive caffeine consumption (defined as *800mg per day) at screening
11. Has used any product containing nicotine within 30 days prior to the inpatient admission
12. Has participated in a clinical trial of an investigational product within 3 months or participated in more than four investigational drug studies within 1 year prior to screening
13. Has lost >500 mL of blood or donated blood within 90 days prior to inpatient admission or donated blood product of any type (eg, plasma) within 14 days prior to inpatient admission
14. Has a history of treatment non-adherence or poor clinic visit attendance or the principal investigator (PI) or designee has reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements
15. Requires a special diet, has a significant food allergy or intolerance, or is not willing to abide by the diet provided by the site
16. Is employed by Alkermes, the investigator or study site, (permanent, temporary contract worker, or designee responsible for the conduct of the study) or is immediate family* of an Alkermes, investigator, or study site employee
* Immediate family is defined as a spouse, parent, sibling, or child, whether biological or

legally adopted

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	20-01-2016
Enrollment:	100
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	ALKS 7119
Generic name:	ALKS 7119

Ethics review

Approved WMO Date:	10-12-2015
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	23-12-2015

Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	15-04-2016
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	22-04-2016
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2015-004488-35-NL
CCMO	NL55561.056.15